GSK Says 'Excellent' Q2 Performance Boosted By Vaccine & HIV Drug Sales, Raises 2023 Outlook
Portfolio Pulse from Vandana Singh
GSK plc reported Q2 FY23 sales of £7.18 billion ($8.97 billion), up 4% Y/Y, in line with consensus. Adjusted EPS of $0.97 beat the Wall Street estimate of $0.87. The company raised its 2023 outlook, expecting turnover to rise by 8%-10% and adjusted operating profit to increase 11%-13%. The results come ahead of the U.S. launch of the company's respiratory syncytial virus vaccine.
July 26, 2023 | 1:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK reported strong Q2 FY23 results and raised its 2023 outlook, which could positively impact its stock price.
GSK's strong Q2 FY23 results and raised 2023 outlook indicate a positive financial performance and future growth prospects, which could make the stock more attractive to investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100